Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Más betegség

• Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.

Életkor

• Persons under the age of 18 years old
  • First-degree relatives would not need to be identified by the participant.
  • This study includes all special populations who fall within the eligible high-risk age range, ≥ 30 years of age, including adults unable to consent, pregnant women, and prisoners. These populations will not be excluded as this is a non-therapeutic study.

Egyéb

• Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia

• Age ≥ 30 years
• AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
  • OR
• Those over 18 are also eligible if they have 2 or more family members with a blood cancer
• Screened positive by mass spectrometry in the Ghobrial Lab for SMM or MGUS as part of the Mass General Brigham Biobank arm AND fits one of the following two groups of criteria:
• Age ≥ 30 years
• AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
  • OR • Those over 18 are also eligible if they have 2 or more family members with a blood cancer
• Screened positive by mass spectrometry in the Ghobrial Lab for SMM or MGUS as part of the Mass General Brigham Biobank arm AND fits the criteria listed below:
• Age ≥ 18 years